Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 16Carboplatin 15Bevacizumab 7Hyperthermic Intraperitoneal Chemotherapy 5Cisplatin 4Taxes 3Gemcitabine 3Cytoreduction Surgical Procedures 3Chemotherapy, Adjuvant 3oregovomab 2niraparib 2fluzoparib 2Topotecan 2ST 1481 2Neoadjuvant Therapy 2Methods 2Immunohistochemistry 2Ifosfamide 2Gene Expression Profiling 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Amplified Fragment Length Polymorphism Analysis 2rucaparib 1pembrolizumab 1paclitaxel poliglumex 1olaparib 1navicixizumab 1mirvetuximab soravtansine 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Fallopian Tube Neoplasms × dostarlimab × Clear all
NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

University Health Network, Toronto

Phase 2 Unknown
40 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡